What is the Success Rate of Spravato

When suffering from depression, especially Treatment-Resistant Depression (TRD), finding an answer to helping reduce symptoms can feel like an uphill battle. When multiple medications and therapies have not worked in the past, patients may turn to newer innovative treatments, like Spravato. Spravato is an FDA-approved treatment that has brought relief to many people who have not responded to traditional antidepressants. But when trying to decide if this is the right path for you, one of the most common questions is, what is the success rate of Spravato?

Success can mean different things depending on the person and how treatment is measured. Still, both clinical studies and real-world experiences offer helpful insight into what patients can expect.

What Does Success Mean in Depression Treatment?

Before exploring the numbers, we have to define what success means in the context of depression treatment. When doctors talk about “success,” they are usually talking about two key outcomes:

• Response: a noticeable reduction in depressive symptoms, usually measured as a 50% improvement.
• Remission: Symptoms improve enough that the person no longer meets the criteria for depressive disorder.

For some patients, having their symptoms cut in half is life-changing. For others, remission is the goal. Either way, these measures help to understand how effective Spravato can be.

What the Research Shows

Spravato gained approval from the FDA in 2019 through several clinical studies. These trials evaluated patients with TRD who had not improved after trying two or more different antidepressants.

• In the studies, about 50% of patients experienced significant symptom improvement when using Spravato alongside an oral antidepressant. 
• Roughly 30-40% reached remission after continuing treatment.
• Some patients began noticing improvement as quickly as 24-48 hours after their first session. This is a unique aspect of Spravato compared to traditional medication, which usually takes weeks to notice improvement.

While these numbers are not guarantees, they highlight how Spravato provides real relief for a large number of people who otherwise had limited options for relief.

Real-World Outcomes

Clinical trials are controlled, but what happens in the real world is just as important. Since its approval, thousands of patients across the country have received Spravato, giving us a larger sense of long-term outcomes.

• Many people who had previously spent years cycling through different medications found noticeable relief from Spravato
• Some patients required long-term maintenance treatments, often weekly or bi-weekly, to sustain improvement
• Others transitioned off Spravato after a period of progress, and then turned to relying mainly on therapy or oral medication

The takeaway here is that patient experiences vary, but for people who haven’t responded to traditional options, Spravato creates a new path forward.

What Affects the Chances of Success?

There are several factors that can influence how well Spravato works for someone:

• Individual biology: Brain chemistry and genetics play a role
• Depression history: People may have histories of long-term or severe depression that may require longer treatment
• Other health conditions: Both physical and mental health can affect results
• Consistency: Being consistent with the induction and maintenance treatment schedule is important
• Support system: Combining Spravato with therapy and continual follow-up usually leads to better outcomes

Important Things to Keep in Mind

Spravato may not be the right fit for everyone. Some patients don’t respond, while others may find the side effects or the treatment schedule difficult. Cost and insurance coverage can also affect access for some.

That’s why it’s important to view Spravato as one tool. It is effective for many, but not a guaranteed cure. Success can often look like meaningful symptom relief and a return to daily functioning, even if the depression does not disappear entirely. 

What This Means for Patients

This means that, according to the trials, about half of patients with TRD are expected to have a meaningful response to Spravato, and up to 40% of these people are also likely to achieve sustained full remission. While these numbers can fluctuate, the results show that Spravato has allowed many patients to regain stability and quality of life. The next step is always to speak with a qualified provider. If standard treatments haven’t helped you find relief, Spravato could be the treatment that finally makes a difference.

Final Thoughts

Spravato is an important step forward in modern depression care. For many patients, it provides the breakthrough they’ve been waiting for. Spravato has given hope where hope once felt out of reach. If you want to learn more about Spravato or find clinics near you that provide this treatment, visit MDDCare.com.